News

FDA Panel: Modafinil Is Not Safe for Treating ADHD in Teens


 

The Drug Enforcement Administration has deemed modafinil a schedule IV drug; other stimulants used to treat ADHD, such as Ritalin, are schedule II.

Despite potential advantages, the panel did not want modafinil to be marketed for children yet.

“I think we did err on the side of consumer protection,” said Dr. Goodman.

Pages

Recommended Reading

Viewing Addiction as a Syndrome Will Open Doors
MDedge Family Medicine
U.S. Surveys Show Paths to Addiction Treatment
MDedge Family Medicine
Consider Ethnicity When Screening for Depression
MDedge Family Medicine
Watch for Growth Slowdown With Stimulants
MDedge Family Medicine
Studies Backing Drug Use For Autism Are Limited
MDedge Family Medicine
Senate Report Puts Kink in VNS Device Coverage
MDedge Family Medicine
Behavior Modification Can Lower Doses of ADHD Drugs in Children
MDedge Family Medicine
Restless Legs Syndrome Tied to Jump in Depression Incidence
MDedge Family Medicine
British Agency Cites Atomoxetine Risks
MDedge Family Medicine
Obsessive-compulsive disorder: Tools for recognizing its many expressions
MDedge Family Medicine